FBR analysts are out with a commentary on updates announced by biotech stocks Juno Therapeutics Inc (NASDAQ:JUNO) and Peregrine Pharmaceuticals (NASDAQ:PPHM). Juno Therapeutics Inc FBR analyst Edward …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, today provided a clinical …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, today announced a new research …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, today announced that it has …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, today announced financial results …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced that its Board of Directors has declared a quarterly cash dividend payment on the Company’s 10.50% Series E Convertible Preferred …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, announced positive new data from …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, today announced the presentation of …
On August 24, Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) announced two new clinical collaborations to expand on the company’s previous immuno-oncology combinations or drugs that fight …
AstraZeneca plc (ADR) (NYSE:AZN) and Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, …
